Tag: Xarelto
New real-world study finds long-term rivaroxaban use resulted in fewer strokes...
Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
Janssen seeks approval for rivaroxaban to be used to reduce cardiac...
Janssen has submitted a supplemental new drug application to the US FDA for two new indications for rivaroxaban (Xarelto, which is marketed by Bayer in...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
European Medicines Agency issues positive opinion for rivaroxaban
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on a label update...
COMPASS study of Janssen’s rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...